Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP):MT-7117 Trial

Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP):MT-7117 Trial

About this clinical trial

Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) are rare genetic disorders that can lead to pain when the skin is exposed to sunlight.

This project aims to investigate whether an experimental drug called MT-7117 is effective and well tolerated in reducing the severity of symptoms.

Patients Required

Estimated completion

August 2022

Total participants required


Study location

The Wesley Hospital

Trial title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)


Inclusion criteria:

  1. Male and female subjects aged >12 to <75 years. 
  2. Confirmed diagnosis of EPP or XLP based on medical history, 
  3. Body weight of ≥30 kg.  
  4. Able to go outside during daylight hours most days (e.g. between 1 hour post sunrise and 1 hour pre-sunset) during the study. 

Additional information

You can find out more about this clinical trial by visiting the ClinicialTrials.gov website.

Lead investigator

Professor David Coman

If you would like more information about this clinical trial, please complete the contact form


Wesley Medical Research

Scroll to Top